Cellectar Biosciences Inc Financials

CLRB

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Cellectar Biosciences Inc (CLRB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 22 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

3/9

Cellectar Biosciences Inc passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

1.07x

For every $1 of reported earnings, Cellectar Biosciences Inc generates $1.07 in operating cash flow (-$47.6M OCF vs -$44.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Revenue

N/A

EBITDA

-$51.5M

YoY-32.8%

Cellectar Biosciences Inc's EBITDA was -$51.5M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 32.8% from the prior year.

Free Cash Flow

-$47.7M

YoY-43.5%

Cellectar Biosciences Inc generated -$47.7M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 43.5% from the prior year.

Net Income

-$44.6M

YoY-4.2%

Cellectar Biosciences Inc reported -$44.6M in net income in fiscal year 2024. This represents a decrease of 4.2% from the prior year.

EPS (Diluted)

$-1.40

Cellectar Biosciences Inc earned $-1.40 per diluted share (EPS) in fiscal year 2024. This represents an increase of 60.0% from the prior year.

Cash & Debt

$23.3M

YoY+143.5%

5Y CAGR+17.0%

10Y CAGR+9.5%

Cellectar Biosciences Inc held $23.3M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

Cellectar Biosciences Inc had 2M shares outstanding in fiscal year 2024. This represents a decrease of 92.6% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

$26.1M

YoY-4.1%

5Y CAGR+23.8%

10Y CAGR+15.9%

Cellectar Biosciences Inc invested $26.1M in research and development in fiscal year 2024. This represents a decrease of 4.1% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$104K

YoY-87.9%

5Y CAGR+33.5%

10Y CAGR+13.4%

Cellectar Biosciences Inc invested $104K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 87.9% from the prior year.

CLRB Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$26.1M-4.1%	$27.3M+49.3%	$18.3M+3.9%	$17.6M+73.4%	$10.1M+12.7%	$9.0M
SG&A Expenses	$25.6M+119.3%	$11.7M+10.9%	$10.5M+61.2%	$6.5M+27.1%	$5.1M-0.6%	$5.2M
Operating Income	-$51.8M-32.9%	-$39.0M-35.2%	-$28.8M-19.4%	-$24.1M-57.8%	-$15.3M-7.8%	-$14.2M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$66K+210.0%	-$60K0.0%	-$60K	N/A	N/A	$0
Net Income	-$44.6M-4.2%	-$42.8M-34.5%	-$31.8M-31.8%	-$24.1M-59.8%	-$15.1M-7.1%	-$14.1M
EPS (Diluted)	$-1.40	$-3.50+22.4%	$-4.51-3.7%	$-4.35	$-1.84	N/A

Metric	Q3'25	Q3'24	Q4'23	Q3'23	Q4'22	Q3'22	Q2'22	Q1'22
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$2.5M-54.1%	$5.5M	N/A	$7.0M	N/A	$5.2M+25.7%	$4.1M+11.9%	$3.7M
SG&A Expenses	$2.3M-70.3%	$7.8M	N/A	$2.4M	N/A	$2.6M-20.8%	$3.3M+35.1%	$2.4M
Operating Income	-$4.9M+63.6%	-$13.3M	N/A	-$9.4M	N/A	-$7.8M-5.1%	-$7.4M-21.1%	-$6.1M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$4.4M+69.7%	-$14.7M	N/A	-$17.5M	N/A	-$7.5M-33.3%	-$5.6M+9.7%	-$6.2M
EPS (Diluted)	$-1.41+88.4%	$-12.13	N/A	$-1.55	N/A	$-1.23-33.7%	$-0.92	$-1.02

CLRB Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$25.5M+111.0%	$12.1M-44.1%	$21.6M-42.0%	$37.2M-36.6%	$58.7M+378.8%	$12.3M
Current Assets	$24.3M+132.0%	$10.5M-49.1%	$20.5M-43.9%	$36.6M-36.9%	$57.9M+408.9%	$11.4M
Cash & Equivalents	$23.3M+143.5%	$9.6M-51.9%	$19.9M-44.4%	$35.7M-37.5%	$57.2M+438.5%	$10.6M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	$0
Total Liabilities	$9.8M-62.1%	$25.9M+114.5%	$12.1M+190.0%	$4.2M+7.6%	$3.9M+21.1%	$3.2M
Current Liabilities	$9.4M-63.0%	$25.4M+120.5%	$11.5M+188.2%	$4.0M+12.0%	$3.6M+28.6%	$2.8M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$14.3M+194.3%	-$15.2M-285.9%	$8.2M-71.9%	$29.1M-47.0%	$54.8M+504.8%	$9.1M
Retained Earnings	-$247.3M-22.0%	-$202.8M-26.7%	-$160.0M-6.0%	-$150.9M-19.0%	-$126.8M-13.5%	-$111.7M

Metric	Q3'25	Q3'24	Q4'23	Q3'23	Q4'22	Q3'22	Q2'22	Q1'22
Total Assets	$14.6M-42.6%	$25.5M+111.0%	$12.1M-44.0%	$21.6M-0.2%	$21.6M+11.8%	$19.3M-25.4%	$25.9M-19.1%	$32.0M
Current Assets	$13.6M-43.8%	$24.3M+132.0%	$10.5M-48.0%	$20.1M-2.0%	$20.5M+9.4%	$18.8M-25.8%	$25.3M-19.5%	$31.4M
Cash & Equivalents	$12.6M-46.1%	$23.3M+143.5%	$9.6M-49.6%	$19.0M-4.4%	$19.9M+11.7%	$17.8M-28.3%	$24.8M-19.0%	$30.6M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$5.2M-46.4%	$9.8M-62.1%	$25.9M-47.8%	$49.6M+311.1%	$12.1M+68.1%	$7.2M+8.6%	$6.6M-11.8%	$7.5M
Current Liabilities	$4.9M-47.7%	$9.4M-63.0%	$25.4M-15.0%	$29.8M+159.4%	$11.5M+61.6%	$7.1M+9.4%	$6.5M-11.5%	$7.4M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$8.0M-44.1%	$14.3M+194.3%	-$15.2M+45.9%	-$28.0M-443.4%	$8.2M-24.3%	$10.8M-39.9%	$17.9M-22.5%	$23.1M
Retained Earnings	-$263.8M-6.7%	-$247.3M-22.0%	-$202.8M-4.0%	-$194.9M-21.8%	-$160.0M-8.4%	-$147.6M-5.4%	-$140.1M-4.2%	-$134.4M

CLRB Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$47.6M-47.0%	-$32.4M-28.4%	-$25.2M-11.8%	-$22.6M-62.0%	-$13.9M-19.1%	-$11.7M
Capital Expenditures	$104K-87.9%	$864K+282.4%	$226K+59.9%	$141K+126.7%	$62K+154.1%	$25K
Free Cash Flow	-$47.7M-43.5%	-$33.2M-30.6%	-$25.4M-12.1%	-$22.7M-62.3%	-$14.0M-19.4%	-$11.7M
Investing Cash Flow	-$104K+87.9%	-$864K-282.4%	-$226K-59.9%	-$141K-126.7%	-$62K-154.1%	-$25K
Financing Cash Flow	$61.4M+167.7%	$22.9M+138.7%	$9.6M+669.6%	$1.2M-97.9%	$60.5M+571.1%	$9.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q3'24	Q4'23	Q3'23	Q4'22	Q3'22	Q2'22	Q1'22
Operating Cash Flow	-$4.3M+60.8%	-$10.9M-13.7%	-$9.6M-18.9%	-$8.1M-8.9%	-$7.4M-5.7%	-$7.0M-21.8%	-$5.8M-14.2%	-$5.0M
Capital Expenditures	N/A	$61K-77.0%	$267K	N/A	$118K+1567.9%	$7K-90.0%	$71K+136.0%	$30K
Free Cash Flow	N/A	-$11.0M-11.3%	-$9.9M	N/A	-$7.5M-7.3%	-$7.0M-20.4%	-$5.8M-15.0%	-$5.1M
Investing Cash Flow	N/A	-$61K+77.0%	-$267K	N/A	-$118K-1567.9%	-$7K+90.0%	-$71K-136.0%	-$30K
Financing Cash Flow	$5.8M	$0-100.0%	$441K-98.0%	$22.5M	N/A	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

CLRB Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-175.0%+179.2pp	-354.2%-206.9pp	-147.3%-82.4pp	-64.8%-39.1pp	-25.7%+89.3pp	-115.0%
Current Ratio	2.58+2.2	0.41-1.4	1.78-7.4	9.16-7.1	16.26+12.2	4.11
Debt-to-Equity	0.69+2.4	-1.71-3.2	1.48+1.3	0.14+0.1	0.07-0.3	0.35
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q3'24	Q4'23	Q3'23	Q4'22	Q3'22	Q2'22	Q1'22
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-30.4%+8.9pp	-39.3%	N/A	-81.3%	N/A	-38.9%-17.1pp	-21.8%-2.2pp	-19.5%
Current Ratio	2.77+0.2	2.58+2.2	0.41-0.3	0.67-1.1	1.78-0.9	2.64-1.2	3.89-0.4	4.27
Debt-to-Equity	0.66-0.0	0.69+2.4	-1.71+0.1	-1.77-3.2	1.48+0.8	0.67+0.3	0.37+0.0	0.32
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Edesa Biotech Inc EDSA

$8.5M

Tharimmune Inc THAR

$187.4M

Lisata Therapeutics Inc LSTA

$40.2M

Pulmatrix PULM

$8.8M

Synlogic SYBX

$6.6M

Frequently Asked Questions

Is Cellectar Biosciences Inc profitable?

No, Cellectar Biosciences Inc (CLRB) reported a net income of -$44.6M in fiscal year 2024.

What is Cellectar Biosciences Inc's earnings per share (EPS)?

Cellectar Biosciences Inc (CLRB) reported diluted earnings per share of $-1.40 for fiscal year 2024. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Cellectar Biosciences Inc's EBITDA?

Cellectar Biosciences Inc (CLRB) had EBITDA of -$51.5M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Cellectar Biosciences Inc's free cash flow?

Cellectar Biosciences Inc (CLRB) generated -$47.7M in free cash flow during fiscal year 2024. This represents a -43.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Cellectar Biosciences Inc's operating cash flow?

Cellectar Biosciences Inc (CLRB) generated -$47.6M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Cellectar Biosciences Inc's total assets?

Cellectar Biosciences Inc (CLRB) had $25.5M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Cellectar Biosciences Inc's capital expenditures?

Cellectar Biosciences Inc (CLRB) invested $104K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Cellectar Biosciences Inc spend on research and development?

Cellectar Biosciences Inc (CLRB) invested $26.1M in research and development during fiscal year 2024.

How many shares does Cellectar Biosciences Inc have outstanding?

Cellectar Biosciences Inc (CLRB) had 2M shares outstanding as of fiscal year 2024.

What is Cellectar Biosciences Inc's current ratio?

Cellectar Biosciences Inc (CLRB) had a current ratio of 2.58 as of fiscal year 2024, which is generally considered healthy.

What is Cellectar Biosciences Inc's debt-to-equity ratio?

Cellectar Biosciences Inc (CLRB) had a debt-to-equity ratio of 0.69 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Cellectar Biosciences Inc's return on assets (ROA)?

Cellectar Biosciences Inc (CLRB) had a return on assets of -175.0% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Cellectar Biosciences Inc's cash runway?

Based on fiscal year 2024 data, Cellectar Biosciences Inc (CLRB) had $23.3M in cash against an annual operating cash burn of $47.6M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Cellectar Biosciences Inc's Piotroski F-Score?

Cellectar Biosciences Inc (CLRB) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Cellectar Biosciences Inc's earnings high quality?

Cellectar Biosciences Inc (CLRB) has an earnings quality ratio of 1.07x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.